Dr. Gomella Discusses Precision Medicine in Prostate Cancer

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of precision medicine in prostate cancer.

According to Gomella, the field of prostate cancer is starting to see increased recognition of precision medicine and more targeted therapies. Research needs to be done not just with the tumor, but with germline mutations like BRCA1/2 and ATM, as well as CHEK2 gene germline abnormalities.

These are going to give physicians some directionality for how to treat patients with prostate cancer across the board, explains Gomella. Most of the attention in this area is focused on advanced castration-resistant prostate cancer, perhaps giving clues as to what are the best agents to use. However, the future is going to be in defining the best patients to be screened, which will give them the best outcome in the long term.